BD Reports Strong Q1 2026 Results and Strategic Milestone
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5h ago
0mins
Should l Buy BDX?
Source: PRnewswire
- Strong Performance: BD reported Q1 2026 revenues of $5.252 billion, reflecting a 1.6% year-over-year increase, demonstrating robust growth across key markets and disciplined execution, which positions the company well for future revenue and earnings growth.
- Earnings Growth: The reported diluted earnings per share reached $1.34, up 28.8% from the previous year, indicating successful cost control and operational efficiency, thereby enhancing investor confidence in the company's future performance.
- Strategic Restructuring: BD anticipates completing the merger of its Biosciences and Diagnostic Solutions business with Waters Corporation, marking a significant milestone that will pivot the company towards
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
US Stocks Dip Slightly as Tech Shares Retreat
- Tech Stock Retreat: Technology stocks are broadly down today, contributing to a 0.03% decline in the S&P 500, a 0.34% drop in the Dow Jones, and a 0.17% decrease in the Nasdaq 100, reflecting a cautious investor sentiment following last Friday's sharp gains.
- Bond Yield Pressure: Rising US bond yields, with the 10-year T-note yield up 2 basis points to 4.22%, are exacerbated by Chinese regulators instructing banks to reduce their US debt holdings, reviving concerns over the haven status of US assets and potentially impacting investor confidence.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings and potential market support.
- Economic Data Focus: The market is set to focus on upcoming economic data, including a projected 0.8% increase in the employment cost index on Tuesday and a 2.5% year-over-year rise in the consumer price index on Friday, which will provide guidance on future economic trends.
See More
Becton Dickinson BDX Q1 2026 Earnings Transcript
See More
Becton Dickinson Reports Sales Above Expectations
- Strong Sales Performance: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating the company's stable demand and adaptability in the healthcare sector.
- Segment Performance: The Medical Essentials segment saw a 0.6% sales increase to $1.595 billion, despite impacts from order timing and market share dynamics in China, while U.S. Vascular Access Management continued to gain market share.
- Adjusted Earnings Guidance: The company lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share, below the consensus of $14.72, reflecting uncertainties in future market demand.
- Market Reaction: Becton Dickinson's shares fell 3.77% to $202.10 in premarket trading, indicating investor concerns over the company's high valuation despite a healthy balance sheet.
See More
BD Reports Strong Q1 Earnings Despite Segment Shortfall
- Strong Earnings Report: BD reported adjusted earnings per share of $2.91 and revenue of $5.3 billion for Q1, despite a year-over-year decline of approximately 15%, surpassing market expectations by $0.10 and $100 million, demonstrating resilience amid challenges.
- Life Sciences Segment Shortfall: The Life Sciences segment contributed $766 million, falling short of analysts' projections of $1.3 billion with an 8% year-over-year contraction, indicating market challenges that could impact future growth potential.
- Strategic Transaction Completed: BD announced the completion of a merger with rival Waters for its Biosciences & Diagnostic Solutions business, expecting a $4 billion cash distribution, with $2 billion allocated for share buybacks, aimed at enhancing shareholder value and driving company transformation.
- Stable Outlook Ahead: BD reaffirmed its full-year outlook for FY26, projecting adjusted EPS between $12.35 and $12.65, although this is below the consensus estimate of $14.79, reflecting a cautious approach to future growth prospects.
See More
Waters Completes Merger with BD's Biosciences Business
- Merger Completion: Waters Corporation has successfully completed its merger with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses, establishing a global leader in life sciences and diagnostics, which is expected to drive expansion in high-growth markets.
- New Board Appointment: Dr. Claire M. Fraser has been appointed to the Waters Board, increasing its size to 11 members; with three decades of experience in genomics and molecular diagnostics, her expertise will significantly support the company's growth and value creation.
- New Divisions Established: Following the merger, Waters has established four new divisions focused on high-volume testing and adjacent high-growth markets, aiming to enhance the company's competitiveness in large and small molecule therapeutics, as well as food and environmental testing.
- Equity Structure Adjustment: Post-merger, Waters shareholders own 60.8% of the combined company while BD shareholders hold 39.2%; through a Reverse Morris Trust transaction, BD shareholders will receive Waters stock, further strengthening the company's market position.
See More
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
US Stocks Dip Slightly as Tech Shares Retreat
- Tech Stock Retreat: Technology stocks are broadly down today, contributing to a 0.03% decline in the S&P 500, a 0.34% drop in the Dow Jones, and a 0.17% decrease in the Nasdaq 100, reflecting a cautious investor sentiment following last Friday's sharp gains.
- Bond Yield Pressure: Rising US bond yields, with the 10-year T-note yield up 2 basis points to 4.22%, are exacerbated by Chinese regulators instructing banks to reduce their US debt holdings, reviving concerns over the haven status of US assets and potentially impacting investor confidence.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth is projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating resilience in corporate earnings and potential market support.
- Economic Data Focus: The market is set to focus on upcoming economic data, including a projected 0.8% increase in the employment cost index on Tuesday and a 2.5% year-over-year rise in the consumer price index on Friday, which will provide guidance on future economic trends.
See More
Becton Dickinson BDX Q1 2026 Earnings Transcript
See More
Becton Dickinson Reports Sales Above Expectations
- Strong Sales Performance: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating the company's stable demand and adaptability in the healthcare sector.
- Segment Performance: The Medical Essentials segment saw a 0.6% sales increase to $1.595 billion, despite impacts from order timing and market share dynamics in China, while U.S. Vascular Access Management continued to gain market share.
- Adjusted Earnings Guidance: The company lowered its fiscal 2026 adjusted earnings guidance to $12.35-$12.65 per share, below the consensus of $14.72, reflecting uncertainties in future market demand.
- Market Reaction: Becton Dickinson's shares fell 3.77% to $202.10 in premarket trading, indicating investor concerns over the company's high valuation despite a healthy balance sheet.
See More
BD Reports Strong Q1 Earnings Despite Segment Shortfall
- Strong Earnings Report: BD reported adjusted earnings per share of $2.91 and revenue of $5.3 billion for Q1, despite a year-over-year decline of approximately 15%, surpassing market expectations by $0.10 and $100 million, demonstrating resilience amid challenges.
- Life Sciences Segment Shortfall: The Life Sciences segment contributed $766 million, falling short of analysts' projections of $1.3 billion with an 8% year-over-year contraction, indicating market challenges that could impact future growth potential.
- Strategic Transaction Completed: BD announced the completion of a merger with rival Waters for its Biosciences & Diagnostic Solutions business, expecting a $4 billion cash distribution, with $2 billion allocated for share buybacks, aimed at enhancing shareholder value and driving company transformation.
- Stable Outlook Ahead: BD reaffirmed its full-year outlook for FY26, projecting adjusted EPS between $12.35 and $12.65, although this is below the consensus estimate of $14.79, reflecting a cautious approach to future growth prospects.
See More
Waters Completes Merger with BD's Biosciences Business
- Merger Completion: Waters Corporation has successfully completed its merger with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses, establishing a global leader in life sciences and diagnostics, which is expected to drive expansion in high-growth markets.
- New Board Appointment: Dr. Claire M. Fraser has been appointed to the Waters Board, increasing its size to 11 members; with three decades of experience in genomics and molecular diagnostics, her expertise will significantly support the company's growth and value creation.
- New Divisions Established: Following the merger, Waters has established four new divisions focused on high-volume testing and adjacent high-growth markets, aiming to enhance the company's competitiveness in large and small molecule therapeutics, as well as food and environmental testing.
- Equity Structure Adjustment: Post-merger, Waters shareholders own 60.8% of the combined company while BD shareholders hold 39.2%; through a Reverse Morris Trust transaction, BD shareholders will receive Waters stock, further strengthening the company's market position.
See More
